CL2008000121A1 - Fragmentos de anticuerpos anti-peptido alfabeta humano covalentemente unidos a polietilenglicol; composicion farmaceutica que los comprende; y su uso para tratar o prevenir una condicion asociada con la actividad del peptido alfabeta. - Google Patents

Fragmentos de anticuerpos anti-peptido alfabeta humano covalentemente unidos a polietilenglicol; composicion farmaceutica que los comprende; y su uso para tratar o prevenir una condicion asociada con la actividad del peptido alfabeta.

Info

Publication number: CL2008000121A1
Authority: CL; Chile
Prior art keywords: alphabet; peptide; understands; fragments; treat
Prior art date: 2007-01-18

Application number

CL200800121A

Other languages

English (en)

Inventor

Kelly Renee Bales

Thomas Frank Bumol

Chi-Kin Chow

Ronald Bradley Demattos

Ryan John-Hansen

Uma Kuchibhotla

Jirong Lu

Peter Colon Mcdonnell

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-01-18

Filing date

2008-01-16

Publication date

2008-07-25

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39332186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2008000121(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2008-01-16 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2008-07-25 Publication of CL2008000121A1 publication Critical patent/CL2008000121A1/es

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6893—Pre-targeting systems involving an antibody for targeting specific cells clearing therapy or enhanced clearance, i.e. using an antibody clearing agents in addition to T-A and D-M
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6093—Synthetic polymers, e.g. polyethyleneglycol [PEG], Polymers or copolymers of (D) glutamate and (D) lysine
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/866—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof involving immunoglobulin or antibody fragment, e.g. fab', fab, fv, fc, heavy chain or light chain

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Epidemiology (AREA)
Nanotechnology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Biochemistry (AREA)
General Chemical & Material Sciences (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Medical Informatics (AREA)
Crystallography & Structural Chemistry (AREA)
General Engineering & Computer Science (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Microbiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

CL200800121A 2007-01-18 2008-01-16 Fragmentos de anticuerpos anti-peptido alfabeta humano covalentemente unidos a polietilenglicol; composicion farmaceutica que los comprende; y su uso para tratar o prevenir una condicion asociada con la actividad del peptido alfabeta. CL2008000121A1 (es)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US88543907P	2007-01-18	2007-01-18

Publications (1)

Publication Number	Publication Date
CL2008000121A1 true CL2008000121A1 (es)	2008-07-25

Family

ID=39332186

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CL200800121A CL2008000121A1 (es)	2007-01-18	2008-01-16	Fragmentos de anticuerpos anti-peptido alfabeta humano covalentemente unidos a polietilenglicol; composicion farmaceutica que los comprende; y su uso para tratar o prevenir una condicion asociada con la actividad del peptido alfabeta.

Country Status (26)

Country	Link
US (1)	US8066999B2 (es)
EP (2)	EP2842967B1 (es)
JP (2)	JP5307030B2 (es)
KR (2)	KR101414847B1 (es)
CN (2)	CN103479998B (es)
AR (1)	AR064944A1 (es)
AU (1)	AU2008206555B2 (es)
BR (1)	BRPI0806715A2 (es)
CA (1)	CA2675847C (es)
CL (1)	CL2008000121A1 (es)
CY (2)	CY1116157T1 (es)
DK (1)	DK2121754T3 (es)
EA (1)	EA020979B1 (es)
ES (2)	ES2615454T3 (es)
HR (2)	HRP20150237T1 (es)
IL (2)	IL199838A (es)
LT (1)	LT2842967T (es)
MX (1)	MX2009007691A (es)
PE (1)	PE20081634A1 (es)
PL (1)	PL2121754T3 (es)
PT (2)	PT2842967T (es)
RS (1)	RS53948B1 (es)
SI (2)	SI2842967T1 (es)
TW (1)	TW200836763A (es)
UA (1)	UA95996C2 (es)
WO (1)	WO2008088983A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5694150B2 (ja)	2008-06-20	2015-04-01	ノバルティスアーゲー	タンパク質中の高分子結合領域および凝集しやすい領域を同定するための方法およびその使用
CN102625813A (zh)	2008-06-20	2012-08-01	诺华公司	具有降低的聚集的免疫球蛋白
CN106117348A (zh) *	2009-06-04	2016-11-16	诺华公司	识别IgG结合位点的方法
PE20130527A1 (es)	2010-03-03	2013-05-09	Boehringer Ingelheim Int	Polipeptidos de union a a-beta biparatopicos
JP6231263B2 (ja) *	2012-07-17	2017-11-15	株式会社島津製作所	アフィニティ支持体及びそれを用いた物質の捕捉方法
US10431325B2 (en)	2012-08-03	2019-10-01	Novartis Ag	Methods to identify amino acid residues involved in macromolecular binding and uses therefor
WO2015036553A1 (en) *	2013-09-16	2015-03-19	Novo Nordisk Health Care Ag	Thiol functionalized polymers
KR20150133576A (ko)	2014-05-20	2015-11-30	삼성전자주식회사	화학적 개질된 표적화 단백질 및 그의 이용
JP7448174B2 (ja)	2015-11-09	2024-03-12	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	アミロイドベータ中間領域エピトープおよびそれに対する立体配座選択的抗体
EP3374379A4 (en)	2015-11-09	2019-05-15	The University Of British Columbia	N-TERMINAL EPITOPES IN AMYLOID BETA AND CONFORMATION-SELECTIVE ANTIBODIES
CA3004498A1 (en)	2015-11-09	2017-05-18	Neil R. Cashman	Amyloid beta epitopes and antibodies thereto
TWI735600B (zh)	2016-07-01	2021-08-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
KR102550991B1 (ko)	2016-07-18	2023-07-04	더 유니버시티 오브 브리티쉬 콜롬비아	아밀로이드 베타에 대한 항체
US10988529B2 (en)	2016-08-09	2021-04-27	Eli Lilly And Company	Combination therapy
US20180125920A1 (en)	2016-11-09	2018-05-10	The University Of British Columbia	Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
US12286469B2 (en)	2017-07-18	2025-04-29	The University Of British Columbia	Humanized antibodies binding to amyloid-beta (A-beta)
JP7330164B2 (ja)	2017-07-18	2023-08-21	ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア	アミロイドベータに対する抗体
AU2018308088B2 (en)	2017-07-25	2025-05-29	Truebinding, Inc.	Treating cancer by blocking the interaction of TIM-3 and its ligand
US20210140980A1 (en) *	2018-01-04	2021-05-13	Septa Therapeutics, Inc.	Septapeptides associated with neurodegeneracy
CA3127113A1 (en)	2019-01-30	2020-08-06	Dongxu Sun	Anti-gal3 antibodies and uses thereof
AU2021278935A1 (en)	2020-05-26	2022-12-08	Truebinding, Inc.	Methods of treating inflammatory diseases by blocking Galectin-3
TW202300518A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5278049A (en)	1986-06-03	1994-01-11	Incyte Pharmaceuticals, Inc.	Recombinant molecule encoding human protease nexin
US5004697A (en)	1987-08-17	1991-04-02	Univ. Of Ca	Cationized antibodies for delivery through the blood-brain barrier
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US5753624A (en)	1990-04-27	1998-05-19	Milkhaus Laboratory, Inc.	Materials and methods for treatment of plaquing disease
US5445090A (en)	1991-07-25	1995-08-29	Mim Industries, Inc.	Interchangeable clamp for use in a sewing machine
US5766846A (en)	1992-07-10	1998-06-16	Athena Neurosciences	Methods of screening for compounds which inhibit soluble β-amyloid peptide production
US5837672A (en)	1992-07-10	1998-11-17	Athena Neurosciences, Inc.	Methods and compositions for the detection of soluble β-amyloid peptide
CA2115900A1 (en)	1993-02-22	1994-08-23	Gerald W. Becker	Pharmaceutical screens and antibodies
US5446090A (en)	1993-11-12	1995-08-29	Shearwater Polymers, Inc.	Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
AU692237B2 (en)	1994-02-03	1998-06-04	Picower Institute For Medical Research, The	Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
US5668651A (en) *	1994-03-18	1997-09-16	Sharp Kabushiki Kaisha	Polymer-wall LCD having liquid crystal molecules having a plane-symmetrical bend orientation
US6114133A (en)	1994-11-14	2000-09-05	Elan Pharmaceuticals, Inc.	Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41)
US5688651A (en)	1994-12-16	1997-11-18	Ramot University Authority For Applied Research And Development Ltd.	Prevention of protein aggregation
US5932462A (en)	1995-01-10	1999-08-03	Shearwater Polymers, Inc.	Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5786180A (en)	1995-02-14	1998-07-28	Bayer Corporation	Monoclonal antibody 369.2B specific for β A4 peptide
US6214966B1 (en)	1996-09-26	2001-04-10	Shearwater Corporation	Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US20040121415A1 (en) *	1996-12-10	2004-06-24	King David John	Monovalent antibody fragments
US6218506B1 (en)	1997-02-05	2001-04-17	Northwestern University	Amyloid β protein (globular assembly and uses thereof)
US6413940B1 (en)	1997-02-07	2002-07-02	Nymox Corporation	Pharmaceutically active agents that impede the formation of amyloid by impeding the genesis of DMS
JP3816111B2 (ja)	1997-04-09	2006-08-30	インテレクト・ニューロサイエンシズ・インコーポレーテッド	β−アミロイド末端に特異的な組換え抗体、それをコードするＤＮＡ及びその使用法
US20020086847A1 (en)	1997-04-09	2002-07-04	Mindset Biopharmaceuticals (Usa)	Recombinant antibodies specific for beta-amyloid ends, DNA encoding and methods of use thereof
US6787319B2 (en)	1997-04-16	2004-09-07	American Home Products Corp.	β-amyloid peptide-binding proteins and polynucleotides encoding the same
US6227999B1 (en)	1997-07-09	2001-05-08	Transmisiones Tsp, S.A. De C.V.	Method and apparatus for operating a clutch in an automated mechanical transmission
IT1293511B1 (it)	1997-07-30	1999-03-01	Gentili Ist Spa	Anticorpi monoclonali catalitici ad attivita' proteasica per la lisi selettiva della componente proteica di placche e aggregati correlati
EP0996736A1 (en)	1997-08-11	2000-05-03	Chiron Corporation	Methods for genetically modifying t cells
US6448369B1 (en)	1997-11-06	2002-09-10	Shearwater Corporation	Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
US7964192B1 (en)	1997-12-02	2011-06-21	Janssen Alzheimer Immunotherapy	Prevention and treatment of amyloidgenic disease
TWI239847B (en)	1997-12-02	2005-09-21	Elan Pharm Inc	N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
EP1061954B1 (en)	1998-03-12	2004-06-09	Nektar Therapeutics Al, Corporation	Poly(ethylene glycol) derivatives with proximal reactive groups
DK1078005T3 (da)	1998-05-21	2010-08-09	Univ Tennessee Res Foundation	Fremgangsmåder til amyloidfjernelse ved anvendelse af anti-amyloidantistoffer
EP1409654B1 (en)	1999-06-16	2008-08-20	Boston Biomedical Research Institute	Immunological control of beta-amyloid levels in vivo
DE60016227T2 (de)	1999-08-04	2005-12-15	Northwestern University, Evanston	Globularer aufbau vom amyloid-beta- protein und deren verwendungen
CA2349434A1 (en)	1999-09-03	2001-03-15	Ramot University Authority For Applied Research & Industrial Development Ltd.	Agents and compositions and methods utilizing same useful in diagnosing and/or treating or preventing plaque forming diseases
US6294171B2 (en)	1999-09-14	2001-09-25	Milkhaus Laboratory, Inc.	Methods for treating disease states comprising administration of low levels of antibodies
DK1259562T3 (da)	1999-12-22	2006-04-18	Nektar Therapeutics Al Corp	Sterisk hindrede derivater af vandoplöselige polymerer
US6413507B1 (en)	1999-12-23	2002-07-02	Shearwater Corporation	Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
SI1481992T1 (sl)	2000-02-24	2017-01-31	Washington University St. Louis	Humanizirana protitelesa, ki vežejo amiloidni peptid beta
US20020009445A1 (en)	2000-07-12	2002-01-24	Yansheng Du	Human beta-amyloid antibody and use thereof for treatment of alzheimer's disease
DK1317479T3 (da)	2000-09-06	2009-11-23	Aventis Pharma Sa	Fremgangsmåder og sammensætninger for sygdomme, der er associeret med amyloidosis
US6436386B1 (en)	2000-11-14	2002-08-20	Shearwater Corporation	Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
TWI255272B (en)	2000-12-06	2006-05-21	Guriq Basi	Humanized antibodies that recognize beta amyloid peptide
WO2003015691A2 (en)	2001-08-17	2003-02-27	Eli Lilly And Company	RAPID IMPROVEMENT OF COGNITION IN CONDITIONS RELATED TO A$g(b)
WO2003016466A2 (en)	2001-08-17	2003-02-27	Eli Lilly And Company	ANTI-Aβ ANTIBODIES
DE60224200T2 (de)	2001-08-17	2008-07-10	Eli Lilly And Co., Indianapolis	Assayverfahren für alzheimer-krankheit
JP2005500389A (ja)	2001-08-17	2005-01-06	イーライ・リリー・アンド・カンパニー	Ａβに関連する病態および疾患を治療するための、可溶性Ａβに高い親和性を有する抗体の使用
DK1944040T3 (da)	2001-08-17	2012-10-29	Univ Washington	Analysefremgangsmåde for Alzheimers sygdom
US7166478B2 (en)	2002-03-12	2007-01-23	Enzo Life Sciences, Inc., C/O Enzo Biochem, Inc.	Labeling reagents and labeled targets, target labeling processes and other processes for using same in nucleic acid determinations and analyses
CA2483729A1 (en)	2002-04-25	2003-11-06	Eli Lilly And Company	Method for treating anxiety and mood disorders in older subjects
US7432330B2 (en) *	2002-12-31	2008-10-07	Nektar Therapeutics Al, Corporation	Hydrolytically stable maleimide-terminated polymers
US7575747B2 (en) *	2003-02-10	2009-08-18	Applied Molecular Evolution	Aβ binding molecules
AU2004220325B2 (en) *	2003-06-30	2011-05-12	Domantis Limited	Polypeptides
WO2006040153A2 (en)	2004-10-13	2006-04-20	Ablynx N.V.	Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
PE20061401A1 (es) *	2004-12-15	2006-12-23	Neuralab Ltd	ANTICUERPOS Aß PARA MEJORAR LA COGNICION

2008
- 2008-01-09 EP EP14190162.9A patent/EP2842967B1/en active Active
- 2008-01-09 US US12/521,309 patent/US8066999B2/en not_active Expired - Fee Related
- 2008-01-09 SI SI200831733A patent/SI2842967T1/sl unknown
- 2008-01-09 ES ES14190162.9T patent/ES2615454T3/es active Active
- 2008-01-09 PT PT141901629T patent/PT2842967T/pt unknown
- 2008-01-09 AU AU2008206555A patent/AU2008206555B2/en not_active Ceased
- 2008-01-09 KR KR1020127003094A patent/KR101414847B1/ko not_active Expired - Fee Related
- 2008-01-09 RS RS20150252A patent/RS53948B1/sr unknown
- 2008-01-09 SI SI200831378T patent/SI2121754T1/sl unknown
- 2008-01-09 LT LTEP14190162.9T patent/LT2842967T/lt unknown
- 2008-01-09 KR KR1020097015076A patent/KR101160385B1/ko not_active Expired - Fee Related
- 2008-01-09 HR HRP20150237AT patent/HRP20150237T1/hr unknown
- 2008-01-09 PL PL08713652T patent/PL2121754T3/pl unknown
- 2008-01-09 CA CA2675847A patent/CA2675847C/en not_active Expired - Fee Related
- 2008-01-09 UA UAA200907146A patent/UA95996C2/ru unknown
- 2008-01-09 ES ES08713652.9T patent/ES2535641T3/es active Active
- 2008-01-09 JP JP2009546461A patent/JP5307030B2/ja not_active Expired - Fee Related
- 2008-01-09 DK DK08713652.9T patent/DK2121754T3/en active
- 2008-01-09 EA EA200970694A patent/EA020979B1/ru not_active IP Right Cessation
- 2008-01-09 CN CN201310412048.9A patent/CN103479998B/zh not_active Expired - Fee Related
- 2008-01-09 WO PCT/US2008/050554 patent/WO2008088983A1/en not_active Ceased
- 2008-01-09 BR BRPI0806715-5A patent/BRPI0806715A2/pt not_active IP Right Cessation
- 2008-01-09 MX MX2009007691A patent/MX2009007691A/es not_active Application Discontinuation
- 2008-01-09 CN CN2008800026216A patent/CN101981053B/zh not_active Expired - Fee Related
- 2008-01-09 PT PT87136529T patent/PT2121754E/pt unknown
- 2008-01-09 EP EP08713652.9A patent/EP2121754B1/en active Active
- 2008-01-11 TW TW097101232A patent/TW200836763A/zh unknown
- 2008-01-16 CL CL200800121A patent/CL2008000121A1/es unknown
- 2008-01-17 AR ARP080100214A patent/AR064944A1/es unknown
- 2008-01-17 PE PE2008000153A patent/PE20081634A1/es not_active Application Discontinuation
2009
- 2009-07-13 IL IL199838A patent/IL199838A/en not_active IP Right Cessation
2013
- 2013-06-26 JP JP2013133551A patent/JP5782479B2/ja not_active Expired - Fee Related
2014
- 2014-02-06 IL IL230876A patent/IL230876A/en not_active IP Right Cessation
2015
- 2015-03-31 CY CY20151100312T patent/CY1116157T1/el unknown
2016
- 2016-12-08 HR HRP20161677TT patent/HRP20161677T1/hr unknown
2017
- 2017-01-24 CY CY20171100108T patent/CY1118554T1/el unknown

Also Published As

Publication number	Publication date
CN101981053B (zh)	2013-11-13
LT2842967T (lt)	2017-02-27
EP2121754B1 (en)	2015-02-11
IL230876A0 (en)	2014-03-31
AU2008206555A1 (en)	2008-07-24
KR20140015123A (ko)	2014-02-06
JP5307030B2 (ja)	2013-10-02
JP5782479B2 (ja)	2015-09-24
BRPI0806715A2 (pt)	2011-09-13
SI2842967T1 (sl)	2017-01-31
AR064944A1 (es)	2009-05-06
KR101160385B1 (ko)	2012-07-10
CA2675847C (en)	2014-12-30
AU2008206555B2 (en)	2013-07-04
TW200836763A (en)	2008-09-16
CN103479998B (zh)	2015-11-18
US8066999B2 (en)	2011-11-29
CN103479998A (zh)	2014-01-01
CY1116157T1 (el)	2017-02-08
HK1190623A1 (zh)	2014-07-11
EA020979B1 (ru)	2015-03-31
HRP20161677T1 (hr)	2017-01-27
RS53948B1 (sr)	2015-08-31
EP2121754A1 (en)	2009-11-25
CA2675847A1 (en)	2008-07-24
CN101981053A (zh)	2011-02-23
IL199838A (en)	2014-03-31
KR101414847B1 (ko)	2014-07-03
EP2842967B1 (en)	2016-11-30
MX2009007691A (es)	2009-07-29
PE20081634A1 (es)	2008-11-22
ES2535641T3 (es)	2015-05-13
PL2121754T3 (pl)	2015-07-31
EA200970694A1 (ru)	2010-02-26
PT2842967T (pt)	2017-01-13
SI2121754T1 (sl)	2015-03-31
HRP20150237T1 (hr)	2015-04-10
JP2013241420A (ja)	2013-12-05
KR20090101941A (ko)	2009-09-29
PT2121754E (pt)	2015-05-11
JP2010522141A (ja)	2010-07-01
ES2615454T3 (es)	2017-06-07
DK2121754T3 (en)	2015-02-23
EP2842967A1 (en)	2015-03-04
IL230876A (en)	2016-06-30
UA95996C2 (ru)	2011-09-26
US20100015155A1 (en)	2010-01-21
IL199838A0 (en)	2010-04-15
WO2008088983A1 (en)	2008-07-24
CY1118554T1 (el)	2017-07-12

Publication	Publication Date	Title
CL2008000121A1 (es)	2008-07-25	Fragmentos de anticuerpos anti-peptido alfabeta humano covalentemente unidos a polietilenglicol; composicion farmaceutica que los comprende; y su uso para tratar o prevenir una condicion asociada con la actividad del peptido alfabeta.
CL2008000910A1 (es)	2008-11-21	Proteina de fusion que comprende una proteina que corta el peptido beta amiloide; composicion farmaceutica que la comprende, y su uso para prevenir y/o tratar enfermedades relacionadas con el peptido beta amiloide.
CL2011003350A1 (es)	2012-06-08	Compuestos derivados de heterociclo nitrogenados, moduladores pkm2; composicion farmaceutica que los comprende; y su uso en el tratamiento del cancer.
CL2007003685A1 (es)	2008-06-27	Compuestos derivados de indol con un anillo unido en las posiciones 4 y 5; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral.
CL2007003684A1 (es)	2008-07-18	Compuestos derivados de indol con un anillo unido en las posiciones 5 y 6; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion viral.
CL2008001467A1 (es)	2008-12-05	Peptidos cilindricos antagonistas de cxcr4 ciclado por lactamas: composicion farmaceutica que los comprenden; y su uso para tratar artitis reumatica, fibrosis pulmonar, infeccion por vih o cancer.
CL2007003303A1 (es)	2008-06-27	Molecula de enlace para la proteina lingo-1; polinucleotido que la codifica; vector y celula que lo comprenden; composicion farmaceutica que comprende la molecula de enlace; y su uso para el tratamiento de lesiones del sistema nervioso central.
CL2008000791A1 (es)	2008-05-30	Compuestos derivados de 2-amino-5-(4-difluorometoxi-fenil)-5-fenil-imidazolidin-4-ona; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la actividad bace excesiva, tales como enferm
CL2013000801A1 (es)	2013-11-29	Composicion farmaceutica que comprende un inhibidor de rankl y una hormona o un derivado de la misma, y uso del inhibidor rankl para preparar dicha composicion
CL2013001107A1 (es)	2014-01-10	Polipeptido derivado de la il-2 con actividad agonista; proteina de fusion que lo comprende; composicion farmaceutica que lo comprende; y su uso para tratar cancer y enfermedades infecciosas cronicas.
CL2007003520A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2007003726A1 (es)	2008-05-16	Anticuerpos anti-receptor del factor del crecimiento similar a la insulina i (igf-ir); composicion farmaceutica que lo contiene; y su uso para tratar el cancer.
CL2007003686A1 (es)	2008-06-27	Compuestos derivados de indol con anillo unido en las posiciones 4,5; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para tratar una infeccion viral.
CL2008001002A1 (es)	2008-10-17	Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
BRPI0814593A2 (pt)	2015-01-20	Composto, composição farmacêutica que o contém e uso do composto.
CL2008001983A1 (es)	2008-10-24	Compuestos derivados de ftalazinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar enfermedades vasculares, shock septico, lesiones isquemicas, neurotoxicidad, shock hemorragico, infecciones virales, entre otras.
BR112012016398A2 (pt)	2018-08-21	Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
CL2008001003A1 (es)	2008-10-17	Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana.
CL2015002941A1 (es)	2016-07-22	Usos terapéuticos de empaglifozina
CL2013002673A1 (es)	2014-07-25	Composicion que comprende un polipéptido aislado con actividad inhibidor de nav1.3 y nav1.7; composicion farmacéutica que comprende la composicion antes dicha; metodo para tratar dolor.
CL2007003523A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CL2012002606A1 (es)	2013-10-18	Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
IL216006A (en)	2015-03-31	Substituted aromatic compounds, pharmaceutical compositions comprising them and use thereof in the manufacture of medications
BRPI0922686A2 (pt)	2018-05-29	associação de licopeno, polifenol e vitaminas para o cuidado das matérias queratínicas
CL2008000442A1 (es)	2008-08-22	Composicion farmaceutica que comprende a un quitosano, un ingrediente activo cosmetico o farmaceutico, y un solvente volatil; y su uso para tratar psoriasis, micosis entre otras enfermedades.